Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Montag A & Associates Inc.

Montag A & Associates Inc. lessened its stake in Edwards Lifesciences Co. (NYSE:EW) by 0.4% in the 4th quarter, Holdings Channel reports. The firm owned 51,953 shares of the medical research company’s stock after selling 208 shares during the period. Montag A & Associates Inc.’s holdings in Edwards Lifesciences were worth $3,961,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. AustralianSuper Pty Ltd acquired a new stake in shares of Edwards Lifesciences during the fourth quarter worth about $168,519,000. Nordea Investment Management AB boosted its stake in shares of Edwards Lifesciences by 1,224.1% during the fourth quarter. Nordea Investment Management AB now owns 1,610,412 shares of the medical research company’s stock worth $123,261,000 after buying an additional 1,488,791 shares during the period. Wellington Management Group LLP boosted its stake in shares of Edwards Lifesciences by 9.2% during the third quarter. Wellington Management Group LLP now owns 16,434,401 shares of the medical research company’s stock worth $1,138,575,000 after buying an additional 1,390,427 shares during the period. FMR LLC boosted its stake in shares of Edwards Lifesciences by 61.1% during the third quarter. FMR LLC now owns 3,111,385 shares of the medical research company’s stock worth $215,557,000 after buying an additional 1,179,637 shares during the period. Finally, J.P. Morgan Private Wealth Advisors LLC acquired a new stake in shares of Edwards Lifesciences during the third quarter worth about $60,971,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on EW shares. Morgan Stanley increased their price target on shares of Edwards Lifesciences from $95.00 to $103.00 and gave the stock an “overweight” rating in a report on Thursday, March 21st. Evercore ISI cut their price target on shares of Edwards Lifesciences from $92.00 to $89.00 and set an “in-line” rating for the company in a report on Friday, April 26th. Piper Sandler increased their price target on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the stock a “neutral” rating in a report on Friday, April 26th. Oppenheimer increased their price target on shares of Edwards Lifesciences from $93.00 to $100.00 and gave the stock an “outperform” rating in a report on Monday, March 18th. Finally, Mizuho increased their target price on shares of Edwards Lifesciences from $95.00 to $105.00 and gave the company a “buy” rating in a report on Thursday, April 11th. One research analyst has rated the stock with a sell rating, six have given a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $93.27.

Edwards Lifesciences Stock Up 2.7 %

Shares of EW traded up $2.33 during midday trading on Thursday, hitting $87.42. The company had a trading volume of 3,421,899 shares, compared to its average volume of 3,709,712. The company’s 50 day moving average price is $90.03 and its 200 day moving average price is $79.73. The stock has a market cap of $52.68 billion, a price-to-earnings ratio of 37.68, a PEG ratio of 3.59 and a beta of 1.10. Edwards Lifesciences Co. has a 52 week low of $60.57 and a 52 week high of $96.12. The company has a quick ratio of 2.67, a current ratio of 3.75 and a debt-to-equity ratio of 0.08.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.02. The company had revenue of $1.60 billion during the quarter, compared to analyst estimates of $1.58 billion. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. On average, equities research analysts predict that Edwards Lifesciences Co. will post 2.77 EPS for the current year.

Insider Buying and Selling

In other news, VP Daniel J. Lippis sold 857 shares of the business’s stock in a transaction that occurred on Tuesday, May 7th. The shares were sold at an average price of $85.60, for a total transaction of $73,359.20. Following the sale, the vice president now owns 23,890 shares in the company, valued at $2,044,984. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, VP Daniel J. Lippis sold 857 shares of the business’s stock in a transaction that occurred on Tuesday, May 7th. The shares were sold at an average price of $85.60, for a total transaction of $73,359.20. Following the sale, the vice president now owns 23,890 shares in the company, valued at $2,044,984. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Bernard J. Zovighian acquired 580 shares of the company’s stock in a transaction on Monday, May 6th. The stock was bought at an average price of $85.74 per share, for a total transaction of $49,729.20. Following the purchase, the chief executive officer now owns 3,268 shares in the company, valued at approximately $280,198.32. The disclosure for this purchase can be found here. Insiders have sold 231,550 shares of company stock worth $20,384,302 in the last ninety days. 1.27% of the stock is currently owned by corporate insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.